License Revenue (Details) - USD ($) $ in Thousands	1 Months Ended				3 Months Ended	6 Months Ended
	May 31, 2023	Aug. 31, 2020	Jul. 31, 2018	Jun. 30, 2018	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2022
Licensing Arrangements
Total revenue					$ 3,000	$ 3,000	$ 20
Pharmbio Korea Inc
Licensing Arrangements
Total revenue							$ 20
Pharmbio Korea Inc | Licensing agreements for development and commercialization
Licensing Arrangements
Upfront payment				$ 3,000
Commercialization milestone payments				$ 500
Time period for written notice to terminate license agreement				180 days
Pharmbio Korea Inc | Licensing agreements for development and commercialization | Minimum
Licensing Arrangements
Time period to form a committee prior to the anticipated date of regulatory approval				6 months
Pharmbio Korea Inc | Licensing agreements for development and commercialization | Maximum
Licensing Arrangements
Royalties on product sales, percentage				20.00%
Jiangsu Nhwa Pharmaceutical Co Ltd
Licensing Arrangements
Total revenue					$ 3,000	$ 3,000
Jiangsu Nhwa Pharmaceutical Co Ltd | Licensing agreements for development and commercialization
Licensing Arrangements
Upfront payment			$ 2,500
Withholding taxes	$ 300	$ 300	$ 300
Time period for written notice to terminate license agreement		180 days
Milestone payment upon regulatory approval		$ 3,000
Milestone payment upon regulatory approval in China	$ 3,000
Milestone payment upon sales targets reached in China		$ 6,000
Royalty percentage on net product sales in China after milestones met		10.00%
License revenue | Licensing agreements for development and commercialization
Licensing Arrangements
Withholding taxes				$ 500